Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in BRAF V600-mutant non-melanoma cancers and multiple myeloma
CTR20131090Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in Nonhematologic neoplasms, multiple myeloma (MM), colorectal cancer (CRC), sponsored by Roche. Started Nov 2014; status: active.
02
Drugs
vemurafenib
03
Conditions
Nonhematologic neoplasmsmultiple myeloma (MM)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20131090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131090.